Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Centruroides immune Fab (equine) - Instituto Bioclon/Rare Disease Therapeutics

Drug Profile

Centruroides immune Fab (equine) - Instituto Bioclon/Rare Disease Therapeutics

Alternative Names: Anascorp; Scorpion immune Fab (equine)

Latest Information Update: 18 Mar 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Instituto Bioclon
  • Developer Instituto Bioclon; Rare Disease Therapeutics
  • Class Antibodies; Antivenins; Fab fragments
  • Mechanism of Action Scorpion venom inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scorpion venom poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Scorpion venom poisoning

Most Recent Events

  • 03 Aug 2011 Registered for Scorpion venom poisoning in USA (IV)
  • 03 Aug 2011 Efficacy and adverse events data from a clinical trial in Scorpion venom poisoning released by the US FDA
  • 24 Aug 2005 Phase-II clinical trials in Scorpion venom poisoning in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top